Key points are not available for this paper at this time.
PurposeTo report the long-term outcomes of a non-inferiority randomized controlled trial (RCT) with a binocular eye-tracking-based home treatment (CureSight; NovaSight, Ltd, Airport City, Israel) in patients with amblyopia.DesignProspective, multicenter, non-randomized, long-term follow-up observational study of an RCT.MethodsForty-three children 4 to 0.05). At 1 year there was a partial reduction in the amblyopic eye VA gain of 0.085±0.1 logMAR compared to end-of-treatment (p=0.001), but the residual gain of 0.20±0.14 logMAR compared to baseline was statistically significant (p0.05). Amblyopia recurrence (a worsening of ≥2 logMAR levels compared with end-of-treatment) occurred in 2/38 patients at 12-weeks post-treatment (5.3%), and in 5/27 patients at 1-year post-treatment (20.4%).ConclusionsVA and stereopsis gains following binocular treatment with CureSight were maintained at 1 year without additional treatment.
Wygnanski-Jaffe et al. (Wed,) studied this question.